Tesamorelin 10mg (Egrifta)
Research Use Only
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
Purity / Result
99.05% +/- 0.18%
Mass / Quantity
9.81 mg
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
Tesamorelin became the newest peptide approved by the FDA for use in HIV-associated lipodystrophy in 2010, reducing adiposity by nearly 20% in this population. Beyond lipodystrophy, research shows tesamorelin reduces triglyceride levels, total cholesterol, and non-HDL-C levels. It is under investigation for improving peripheral nerve regeneration, where growth hormone manipulation may increase both rate and extent of healing. A large randomized, double-blind, placebo-controlled study suggests tesamorelin enhances cognition in patients with early-stage dementia by increasing GABA levels and decreasing myo-inositol levels in the brain. This 10mg vial provides extended material for comprehensive GH-axis modulation research.
Frequently Bought Together
Tesamorelin 10mg
10mg
$64 USD
Bundle & Save
$99 USD
Save $4 USD
$149 USD
Save $14 USD
$194 USD
Save $29 USD
$229 USD
Save $44 USD
Click any product above to toggle selection
Related Peptides
What Is Tesamorelin?
Tesamorelin is a growth hormone releasing hormone (GHRH) analogue consisting of standard GHRH to which an additional trans-3-hexanoic acid group has been added. Tesamorelin became the newest peptide to be approved by the FDA for use in HIV-associated lipodystrophy in 2010. The peptide has also been investigated for its ability to improve peripheral nerve regeneration and as a potential intervention for mild cognitive impairment (MCI), the precursor to dementia.
Tesamorelin Peptide Structure
| Molecular Formula | C223H370N72O69S |
| Molecular Weight | 5195.908 g/mol |
| PubChem CID | 44147413 |
| CAS Number | 901758-09-6 |
Tesamorelin and Lipodystrophy
The primary use for tesamorelin is in the treatment of HIV-associated lipodystrophy. In 2010, the FDA approved tesamorelin specifically for this condition. The peptide has been found to reduce adiposity by nearly 20%[1]. Research suggests that tesamorelin is approximately 4 times more effective in reducing adiposity than all other available therapies combined[2].
Tesamorelin in Cardiac Disease
People with HIV are at increased risk of developing cardiovascular disease. Research shows that tesamorelin reduces triglyceride levels, total cholesterol levels, and non-HDL-C levels. A 15% reduction in visceral adipose tissue by tesamorelin correlates with a 50 mg decrease in triglyceride levels[3], [4].
Growth Hormone Deficiency and HIV
Recent evidence suggests that HAART is associated with GH deficiency. Approximately one third of patients with HIV who are taking HAART have GH deficiency[5]. Tesamorelin is a safer and more effective way to raise GH levels than administration of exogenous GH.
Tesamorelin for Peripheral Nerve Damage
Peripheral nerve damage can be a consequence of injury, diabetes, or surgical interventions. Research suggests that therapies based on growth hormone manipulation may improve peripheral nerve injury[6]. Tesamorelin is currently the leading candidate for such intervention, in part because it already has FDA approval.
Tesamorelin in Dementia
A large, randomized, double-blind, placebo-controlled study at the University of Washington School of Medicine suggests that tesamorelin and other GHRH analogues may impact dementia by increasing GABA levels in the brain and by decreasing myo-inositol levels[7].
Tesamorelin Summary
Tesamorelin is FDA approved for use in humans, making it attractive for ongoing clinical research. It is currently under review for its ability to reduce cardiovascular disease in HIV, improve healing of peripheral nerves following injury, and slow the progression of dementia.
Article Author
The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.
Referenced Citations
- 1Clinical Review Report: Tesamorelin (Egrifta). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2016.
- 2A. Mangili et al., "Predictors of Treatment Response to Tesamorelin in HIV-Infected Patients with Excess Abdominal Fat," PloS One, vol. 10, no. 10, p. e0140358, 2015.
- 3J. Falutz et al., "Metabolic effects of a growth hormone-releasing factor in patients with HIV," N. Engl. J. Med., vol. 357, no. 23, pp. 2359-2370, Dec. 2007.
- 4T. L. Stanley et al., "Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin," Clin. Infect. Dis., vol. 54, no. 11, pp. 1642-1651, Jun. 2012.
- 5V. Rochira and G. Guaraldi, "Growth hormone deficiency and human immunodeficiency virus," Best Pract. Res. Clin. Endocrinol. Metab., vol. 31, no. 1, pp. 91-111, 2017.
- 6S. H. Tuffaha et al., "Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury," Expert Opin. Ther. Targets, vol. 20, no. 10, pp. 1259-1265, Oct. 2016.
- 7S. D. Friedman et al., "Growth hormone-releasing hormone effects on brain GABA levels in mild cognitive impairment and healthy aging," JAMA Neurol., vol. 70, no. 7, pp. 883-890, Jul. 2013.
Disclaimer
All articles and product information provided on this website are for informational and educational purposes only. The products offered on this website are furnished for in-vitro studies only. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.
Related Research News
Tesamorelin Research Interest Grows Among Synthetic GHRPs
Synthetic growth hormone-releasing peptides (GHRPs) are drawing increasing attention in scientific research, with tesamorelin emerging as a focal point. The compound, a synthetic analog of growth hormone-releasing hormone, is being studied for its potential to modulate growth hormone levels. This article examines the rising research interest in tesamorelin and its place within the broader class of synthetic GHRPs.
Tesamorelin Manufacturing News: Peptide CDMO Market to Reach $11.42B by 2035
The peptide and oligonucleotide CDMO market is projected to reach USD 11.42 billion by 2035, driven by regulatory shifts and increased demand for research compounds. Recent FDA panel recommendations to ease restrictions on peptides like BPC-157 and tesamorelin signal potential manufacturing expansion. This analysis explores capacity changes and industry implications.
FDA Panel Votes to Loosen Regulations on Peptides Including Tesamorelin News
An FDA advisory committee has voted to recommend easing restrictions on four peptides, including BPC-157, TB-500, and reportedly tesamorelin, despite opposition from the agency's own scientists. This decision could reshape the regulatory landscape for peptide research and access.